Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta

agalsidase betaPositive

AI Analysis

Summary

Biosidus announced that its new bioreactor plant is now operational, increasing manufacturing capacity and global supply capabilities for agalsidase beta, a biosimilar medicine.

Importance:3/10

Sentiment:

0.50

manufacturingbiosimilarcapacity expansionbioreactor

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Clinical Trials on August 26, 2026 9:00 PM

Read Original